



Eiger to Participate in Piper Jaffray Healthcare Conference

PALO ALTO, Calif., Nov. 19, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the 30th Annual Piper Jaffray Healthcare Conference on November 27 at 4:00 PM ET at Lotte NY Palace Hotel in New York City.

A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab. A replay of the webcast will be available approximately one hour following the completion of the live event.

Eiger will also host one-on-one meetings with investors.

About Eiger

Eiger is a late-stage biopharmaceutical company focused on the accelerated development and commercialization of a pipeline of targeted therapies for rare and ultra-rare diseases. Our lead program is advancing Lonafarnib into a Phase 3, single pivotal trial to treat Hepatitis Delta Virus (HDV) Infection, initiating in 2018. Eiger is preparing an NDA for Lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) with plans to file in 2019. For additional information about Eiger, please visit www.eigerbio.com.

Investors: Ingrid Choong, PhD

Email: ichoong@eigerbio.com

Phone: 1-650-619-6115

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/eiger-to-participate-in-piper-jaffray-healthcare-conference-300752698.html>

SOURCE Eiger BioPharmaceuticals, Inc.

